Mutational analysis of the coding regions of the genes encoding protein kinase B-alpha and -beta, phosphoinositide-dependent protein kinase-1, phosphatase targeting to glycogen, protein phosphatase inhibitor-1, and glycogenin: lessons from a search for genetic variability of the insulin-stimulated glycogen synthesis pathway of skeletal muscle in NIDDM patients

Diabetes. 1999 Feb;48(2):403-7. doi: 10.2337/diabetes.48.2.403.

Abstract

The finding of a reduced insulin-stimulated glucose uptake and glycogen synthesis in the skeletal muscle of glucose-tolerant first-degree relatives of patients with NIDDM, as well as in cultured fibroblasts and skeletal muscle cells isolated from NIDDM patients, has been interpreted as evidence for a genetic involvement in the disease. The mode of inheritance of the common forms of NIDDM is as yet unclear, but the prevailing hypothesis supports a polygenic model. In the present study, we tested the hypothesis that the putative inheritable defects of insulin-stimulated muscle glycogen synthesis might be caused by genetic variability in the genes encoding proteins shown by biochemical evidence to be involved in insulin-stimulated glycogen synthesis in skeletal muscle. In 70 insulin-resistant Danish NIDDM patients, mutational analysis by reverse transcription-polymerase chain reaction-single strand conformation polymorphism-heteroduplex analysis was performed on genomic DNA or skeletal muscle-derived cDNAs encoding glycogenin, protein phosphatase inhibitor-1, phophatase targeting to glycogen, protein kinase B-alpha and -beta, and the phosphoinositide-dependent protein kinase-1. Although a number of silent variants were identified in some of the examined genes, we found no evidence for the hypothesis that the defective insulin-stimulated glycogen synthesis in skeletal muscle in NIDDM is caused by structural changes in the genes encoding the known components of the insulin-sensitive glycogen synthesis pathway of skeletal muscle.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • 3-Phosphoinositide-Dependent Protein Kinases
  • Carrier Proteins / genetics*
  • DNA Mutational Analysis*
  • Diabetes Mellitus, Type 2 / genetics*
  • Diabetes Mellitus, Type 2 / metabolism
  • Endoribonucleases*
  • Female
  • Genetic Variation / physiology
  • Glucosyltransferases
  • Glycogen / biosynthesis
  • Glycoproteins / genetics*
  • Humans
  • Insulin / physiology
  • Intracellular Signaling Peptides and Proteins*
  • Isomerism
  • Male
  • Middle Aged
  • Muscle, Skeletal / metabolism
  • Phenotype
  • Phosphoprotein Phosphatases
  • Protein Serine-Threonine Kinases / genetics*
  • Proto-Oncogene Proteins / genetics*
  • Proto-Oncogene Proteins c-akt
  • RNA-Binding Proteins / genetics*

Substances

  • Carrier Proteins
  • Glycoproteins
  • Insulin
  • Intracellular Signaling Peptides and Proteins
  • PPP1R3C protein, human
  • Proto-Oncogene Proteins
  • RNA-Binding Proteins
  • glycogenin
  • protein phosphatase inhibitor-1
  • Glycogen
  • Glucosyltransferases
  • 3-Phosphoinositide-Dependent Protein Kinases
  • AKT1 protein, human
  • Protein Serine-Threonine Kinases
  • Proto-Oncogene Proteins c-akt
  • Endoribonucleases
  • Phosphoprotein Phosphatases
  • PPP1R8 protein, human

Grants and funding